Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 9/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20760648 | 1.00 | APLNR (0.47) | APLNRTAS2R14BACE1PTGESTAS2R8 | |
| SCHEMBL22497172 | 1.00 | APLNR (0.47) | APLNRTAS2R14BACE1PTGESTAS2R8 | |
| SCHEMBL20757669 | 0.84 | APLNR (0.47) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL20757424 | 0.81 | APLNR (0.46) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL20757151 | 0.80 | MEN1 (0.59) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL22497182 | 0.79 | TAS2R14 (0.48) | APLNRTAS2R14BACE1PTGESTAS2R8 | |
| SCHEMBL22497260 | 0.79 | TAS2R14 (0.48) | APLNRTAS2R14BACE1PTGESTAS2R8 | |
| SCHEMBL20757394 | 0.79 | TAS2R14 (0.48) | APLNRTAS2R14BACE1PTGESTAS2R8 | |
| SCHEMBL23013817 | 0.76 | APLNR (0.45) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL22497253 | 0.76 | TAS2R14 (0.53) | APLNRTAS2R14BACE1PTGESTAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012392-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| US-11926600-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-03-12 | — | — | US | disclosed |
| US-20210122716-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-04-29 | — | — | US | disclosed |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-08 | — | — | US | disclosed |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-08 | — | — | US | disclosed |
| WO-2019034693-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, PYCARD | APLNR 2957/4885TAS2R14 1024/4885BACE1 240/4885 |
| US-11926600-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | APLNR 3932/4885TAS2R14 686/4885BACE1 80/4885 |
| US-12012392-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | APLNR 3254/4885TAS2R14 991/4885BACE1 286/4885 |
| US-20210122716-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | APLNR 3503/4885TAS2R14 1173/4885BACE1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.